Top

Published in:

01-01-2014 | Bone and Soft Tissue Sarcomas

Prognostic Factors in Elderly Osteosarcoma Patients: A Multi-institutional Retrospective Study of 86 Cases

Authors: Shintaro Iwata, MD, Takeshi Ishii, MD, Akira Kawai, MD, Toru Hiruma, MD, Tsukasa Yonemoto, MD, Hiroto Kamoda, MD, Naofumi Asano, MD, Masanobu Takeyama, MD

Published in: Annals of Surgical Oncology | Issue 1/2014

Abstract

Background

The occurrence of osteosarcoma in elderly patients has recently been increasing, and the outcome is poor. This multi-institutional retrospective study was conducted to investigate clinical features and prognostic factors in patients older than 40 years with osteosarcoma.

Methods

Patients with conventional high-grade osteosarcoma older than 40 years were recruited to this study. Secondary osteosarcoma arising from Paget’s disease or irradiated bones was excluded. Information on tumor- and treatment-related factors was collected and statistically analyzed. The median follow-up was 57 months (range 8–244 months) for all surviving patients.

Results

A total of 86 patients were enrolled in this study. The median age at diagnosis was 61 years. Surgery and chemotherapy were conducted in 73 and 63 % of all patients, respectively. The 5-year overall and event-free survival rates were 38.8 and 34.0 %, respectively. Tumor site (extremity 57.9 %; axial 19.0 %; p < 0.0001), metastasis at diagnosis (yes 12.2 %; no 48.3 %; p < 0.0091), and definitive surgery (yes 56.2 %; no 10.6 %; p < 0.0001) were associated with overall survival. Although patients without metastasis who received definitive surgery were regarded as good candidates for chemotherapy, the addition of chemotherapy did not have any impact on the outcome (yes 63.4 %; no 65.2 %; p = 0.511).

Conclusions

The present study revealed the distinct clinical features, such as the high incidence of truncal tumors or metastasis at diagnosis, in patients older than 40 years with osteosarcoma. Additionally, prognostic factor analyses revealed that tumor site, metastasis at diagnosis, definitive surgery, and surgical margins were significant prognostic factors, whereas chemotherapy did not influence survival.

Japan Orthopaedic Association Musculoskeletal Tumor Committee/National Cancer Center. Bone and Soft Tissue Tumor Registry in Japan. 2009.

Bacci G, Ferrari S, Donati D, Longhi A, Bertoni F, Di Fiore M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. Oncol Rep. 1998;5:1259–63.PubMed

Carsi B, Rock MG. Primary osteosarcoma in adults older than 40 years. Clin Orthop. 2002;397:53–61.PubMedCrossRef

Grimer RJ, Cannon SR, Taminiau AM, Bielack S, Kempf-Bielack B, Windhager R, et al. Osteosarcoma over the age of forty. Eur J Cancer. 2003;39:157–63.PubMedCrossRef

Huvos AG. Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years. Cancer. 1986;57:1442–9.PubMedCrossRef

Longhi A, Errani C, Gonzales-Arabio D, Ferrari C, Mercuri M. Osteosarcoma in patients older than 65 years. J Clin Oncol. 2008;26:5368–73.PubMedCrossRef

Manoso MW, Healey JH, Boland PJ, Athanasian EA, Maki RG, Huvos AG, et al. De novo osteogenic sarcoma in patients older than forty: benefit of multimodality therapy. Clin Orthop. 2005;438:110–5.PubMedCrossRef

Naka T, Fukuda T, Shinohara N, Iwamoto Y, Sugioka Y, Tsuneyoshi M. Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma. Cancer. 1995;76:972–84.PubMedCrossRef

Nishida Y, Isu K, Ueda T, Nishimoto Y, Tsuchiya H, Wada T, et al. Osteosarcoma in the elderly over 60 years: a multicenter study by the Japanese Musculoskeletal Oncology Group. J Surg Oncol. 2009;100:48–54.PubMedCrossRef

10.

Okada K, Hasegawa T, Nishida J, Ogose A, Tajino T, Osanai T, et al. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases—an experience in northern Japan. Ann Surg Oncol. 2004;11:998–1004.PubMedCrossRef

11.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American Joint Committee on Cancer Staging Manual. 7th ed. New York: Springer, 2009.

12.

Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop. 1980;153:106–20.PubMed

13.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef

14.

Huvos AG, Rosen G, Marcove RC. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14–8.PubMed

15.

Imai R, Kamada T, Tsuji H, Tsujii H, Tsuburai Y, Tatezaki S. Cervical spine osteosarcoma treated with carbon-ion radiotherapy. Lancet Oncol. 2006;7:1034–5.PubMedCrossRef

16.

Kamada T, Tsujii H, Tsuji H, Yanagi T, Mizoe JE, Miyamoto T, et al. Efficacy and safety of carbon ion radiotherapy in bone and soft tissue sarcomas. J Clin Oncol. 2002;20:4466–71.PubMedCrossRef

17.

Duffaud F, Digue L, Baciuchka-Palmaro M, Volot F, Perles-Daniel C, Garbe L, et al. Osteosarcomas of flat bones in adolescents and adults. Cancer. 2000;88:324–32.PubMedCrossRef

18.

Mankin HJ, Hornicek FJ. Paget’s sarcoma: a historical and outcome review. Clin Orthop. 2005;438:97–102.PubMedCrossRef

19.

Bielack SS, Kempf-Bielack B, Heise U, Schwenzer D, Winkler K. Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. J Clin Oncol. 1999;17:1164–74.PubMed

20.

Bielack SS, Wulff B, Delling G, Göbel U, Kotz R, Ritter J, et al. Osteosarcoma of the trunk treated by multimodal therapy: experience of the Cooperative Osteosarcoma study group (COSS). Med Pediatr Oncol. 1995;24:6–12.PubMedCrossRef

21.

Antman K, Crowley J, Balcerzak SP, Kempf RA, Weiss RB, Clamon GH, et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing’s sarcoma, and rhabdomyosarcoma. Cancer. 1998;82:1288–95.PubMedCrossRef

Title: Prognostic Factors in Elderly Osteosarcoma Patients: A Multi-institutional Retrospective Study of 86 Cases
Authors: Shintaro Iwata, MD
Takeshi Ishii, MD
Akira Kawai, MD
Toru Hiruma, MD
Tsukasa Yonemoto, MD
Hiroto Kamoda, MD
Naofumi Asano, MD
Masanobu Takeyama, MD
Publication date: 01-01-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 1/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3210-4

At a glance: The STEP trials

Springer Medicine

Prognostic Factors in Elderly Osteosarcoma Patients: A Multi-institutional Retrospective Study of 86 Cases

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Complete Cytoreduction and HIPEC Improves Survival in Desmoplastic Small Round Cell Tumor

Society of Surgical Oncology Distinguished Service Award: Honoring David P. Winchester, M.D.

MRI-Based Treatment of Rectal Cancer: Is Prognostication of the Recurrence Risk Solid Enough to Render Radiation Redundant?

Impact of Margin Assessment Method on Positive Margin Rate and Total Volume Excised

Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy

Selective Lateral Pelvic Lymph Node Dissection in Patients with Advanced Low Rectal Cancer Treated with Preoperative Chemoradiotherapy Based on Pretreatment Imaging